Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 5;13:1099–1111. doi: 10.2147/CMAR.S278023

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 Si et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Celastrol exerted anti-tumor effect on tumor growth in vivo by circ_SLIT3. Un-transduced, lenti-NC-infected or lenti-circ_SLIT3-transduced Hep3B cells were implanted under the subcutaneous layer into the nude mice (n = 6 each group). The administration of celastrol (2 mg/kg) was performed after 5 days implantation by intraperitoneal injection every 5 days. (A) Growth curves of the xenograft tumors. (B) The average weight of the excised tumors. The levels of circ_SLIT3 (C), miR-223-3p (D) and CXCR4 mRNA (E) by qRT-PCR and CXCR4 protein expression by Western blot (F) in the xenograft tumors. (G) The expression of CXCR4, Ki67, Bcl-2 and Bax by immunohistochemistry in the xenograft tumors. n = 6; data were presented as mean ± SD; *P < 0.05 or **P < 0.01 vs Control or Cela+lenti-NC.